The First Human Trial of Delta Sleep-Inducing Peptide: 59% More Sleep Without Sedation

Six healthy volunteers (4 male, 2 female) received either DSIP (25 nmol/kg) or placebo via slow intravenous infusion in the morning in a double-blind crossover design. Subjects underwent extensive psychophysiological monitoring including sleep staging, EEG analysis, and behavioral assessment during the immediate post-infusion period and the subsequent night's sleep.

This was one of the first human studies of DSIP, a peptide originally discovered in rabbit brain dialysate. The finding that it increased sleep by 59% without causing sedation was remarkable — suggesting a fundamentally different mechanism from sleeping pills like benzodiazepines. It supported the idea that DSIP enhances natural sleep architecture rather than drug-induced unconsciousness, making it a conceptual predecessor to modern sleep research focused on restoring physiological sleep patterns.

This pioneering 1981 study launched decades of DSIP research and introduced the concept that a peptide could promote sleep through natural mechanisms rather than sedation. While DSIP never became an approved drug (partly due to its short half-life and difficulty with non-IV delivery), the principle it demonstrated — enhancing natural sleep architecture rather than forcing unconsciousness — has influenced modern sleep research and the development of newer sleep-promoting therapies like orexin antagonists.

Extremely small sample of only 6 volunteers limits statistical power and generalizability. The 1981 study predates modern sleep research standards and polysomnographic technology. IV administration is impractical for clinical use. No dose-ranging was performed. The 'median' 59% increase in such a small sample may be heavily influenced by individual variation. Long-term safety and efficacy were not assessed.